Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
Zydelig
|
| gptkbp:chemicalFormula |
C22H23ClN2O4S
|
| gptkbp:clinicalTrials |
Phase 1
combination therapy Phase 2 Phase 3 monotherapy |
| gptkbp:contraindication |
anemia
fatigue nausea abdominal pain vomiting rash active infections thrombocytopenia severe liver impairment hypersensitivity reactions |
| gptkbp:dosageForm |
150 mg twice daily
|
| gptkbp:drugInterdiction |
CYP3A4 inhibitors
CYP3A4 inducers |
| gptkbp:established |
gptkb:Gilead_Sciences
|
| gptkbp:formulation |
tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Idelalisib
|
| gptkbp:issuedBy |
oral tablet
|
| gptkbp:lastProduced |
2014
|
| gptkbp:mandates |
relapsed CLL
relapsed_FL |
| gptkbp:numberOfStudents |
approximately 8 hours
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:offersCoursesIn |
gptkb:Australia
gptkb:Canada gptkb:Japan gptkb:USA EU_countries |
| gptkbp:patentStatus |
patented
|
| gptkbp:researchAreas |
oncology
hematology ongoing studies post-marketing studies |
| gptkbp:safetyFeatures |
monitor blood counts
monitor liver function monitor for infections |
| gptkbp:sideEffect |
diarrhea
hepatotoxicity neutropenia pneumonitis |
| gptkbp:targets |
PI3K_pathway
|
| gptkbp:triggerType |
PI3K_inhibitor
|
| gptkbp:usedFor |
chronic lymphocytic leukemia
follicular lymphoma |
| gptkbp:waterManagement |
urine
feces |